Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
StemX Bio has developed a proprietary animal-free process to generate highly physiologically relevant human pancreatic microtissues from iPSCs. Their flagship product enables more predictive drug discovery and disease modeling in diabetes research by providing all major pancreatic cell types in a ready-to-use format. The technology aims to replace traditional animal models and improve the reliability of early-stage drug testing[1][3]. Initial clinical results are not applicable as this is a research tool/platform company.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on StemX Bio.